Pharmaceuticals News and Research

RSS

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

Scientists at Cincinnati Children's Hospital Medical Center have discovered that a diet with high levels of fructose - levels equivalent to that in high fructose corn syrup - and of trans fats not only increases obesity, but also leads to significant fatty liver disease with scar tissue.

23 Jun 2010

A*STAR physicist receives prestigious 2010 IEEE Medal for Innovations in Healthcare Technology

Physicist David William Townsend will be honoured with the prestigious 2010 IEEE Medal for Innovations in Healthcare Technology for the design, commercial development and clinical implementation of the PET/CT scanner. Prof Townsend will receive the medal jointly with his co-inventor, engineer Ronald Nutt, on 26 June 2010 at the IEEE Honors Ceremony in Montreal, Quebec, Canada. IEEE is the world's largest professional association advancing technology for humanity.

23 Jun 2010

Prosensa, GSK initiate additional programs for DMD

Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa's "exon skipping" platform and the ongoing relationship.

23 Jun 2010

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

For the very first time, a medicine has been shown to protect against the development of Alzheimer's disease. French scientists were able to demonstrate that taking 240 mg of Ginkgo extract EGb 761 per day regularly over a period of at least 4 years can cut the risk of developing Alzheimer's disease by nearly 50%.

23 Jun 2010

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

Nymox Pharmaceutical Corporation is pleased to report positive new results from the 48-60 month follow-up study of patients treated with NX-1207 in Study NX02-0014. The initial study, completed in the U.S. in 2006, reached statistical significance in Intent-to-Treat Primary Efficacy outcomes at 90 days post-treatment with NX-1207 2.5 mg.

23 Jun 2010

European drugmakers lead in making medicines available to developing world, Index says

European drug companies came out ahead of their U.S. counterparts in making medicines available to people in developing countries, but their lead is beginning to shrink, according to the Access to Medicines Index, released on Monday, Reuters reports (Kelland, 6/21).

23 Jun 2010

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

OvaGene Oncology Inc., a biotechnology company specializing in the development and commercialization of personalized DNA-based diagnostics for gynecologic cancer, announced today the opening of its new clinical and research laboratory in Irvine, California. This state-of-the-art facility will serve as the central headquarters for operations, research, and molecular clinical lab testing.

23 Jun 2010

Weikang Bio-Technology files for listing on NASDAQ

Weikang Bio-Technology Group Co., Inc., a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company had filed an application to list its common stock on the NASDAQ Capital Market.

23 Jun 2010

FDA approves Hospira's meropenem for injection, USP (I.V.)

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has received U.S. Food and Drug Administration (FDA) approval for meropenem for injection, USP (I.V.) 500 mg and 1 g vials. The medication, a carbapenem that belongs to the beta-lactam class of antibiotics, is a generic version of AstraZeneca's Merrem® I.V. Sales of the name-brand product in the United States were approximately $200 million in 2009.

23 Jun 2010

iCAD image analysis software program used in DCE-MRI studies demonstrated at ASCO 2010

ACR Image MetrixTM, an imaging contract research organization with expertise in imaging trial design, techniques and data extraction, in conjunction with its software partner, iCAD, gave demonstrations of the iCAD image analysis software program used in DCE-MRI studies at the ACR Image Metrix booth during the 2010 Annual American Society of Clinical Oncology Meeting, which took place June 4-8, 2010, in Chicago, IL.

23 Jun 2010

Nuon study confirms potential utility of tranilast as uricosuric agent

Nuon Therapeutics, Inc., a privately held, clinical stage biopharmaceutical company, announced that results from clinical and preclinical studies demonstrating the ability of tranilast to reduce serum uric acid levels and monosodium urate crystal-induced inflammation - two important risk factors for gout - were presented at The European League Against Rheumatism (EULAR) 2010 Annual European Congress of Rheumatology in Rome, Italy, June 16-19, 2010.

22 Jun 2010

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Ricerca Biosciences, a uniquely integrated preclinical contract research drug development company providing services to the pharmaceutical industry, is pleased to announce that its Ricerca France, Lyon facility, has recently obtained the ISO 9001:2008 certification for all activities performed at the site.

22 Jun 2010

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Probactive Biotech, Inc., a Garden Grove, California-based corporation, has entered into an agreement with Dalat Nuclear Research Institute to co-develop a number of cancer drugs, utilizing combinations of antitumor antibodies and antitumor radioactive compounds. Antitumor antibodies have the ability to take antitumor compounds directly to the tumor sites within the body.

22 Jun 2010

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Ensemble Discovery today announced that it will begin operating as Ensemble Therapeutics Corporation to reflect the Company's progress and emerging pipeline by applying its macrocycle drug platform to develop novel therapeutics. The new name, Ensemble Therapeutics, conveys the company's leadership and advancement in developing novel macrocycle drug compounds that are small molecules with expanded therapeutic properties of large molecule biological drugs.

22 Jun 2010

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Affymax, Inc. today announced that it has received $30 million in development milestone payments from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™/peginesatide, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients.

22 Jun 2010

Metabolex signs global development and license agreement with OMJPI

Metabolex, Inc. announced today that they have entered into a global development and license agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop and discover compounds for the treatment of type 2 diabetes and other disorders. Under the agreement, OMJPI will receive an exclusive worldwide license to develop, manufacture, and commercialize several Metabolex programs that are currently at the preclinical stage.

22 Jun 2010

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

Three leading scientists in the field of cardiac safety in pre-clinical drug development are gathering to discuss Improved Strategies for Pre-clinical Cardiac Testing in a free webinar on June 23 at 11:00 a.m. EDT, sponsored by the Drug Safety Council.

22 Jun 2010

USPTO issues patent related to Derma Sciences' MEDIHONEY Calcium Alginate Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, announces that the U.S. Patent and Trademark Office has issued patent No. 7,714,183 related to the Company's MEDIHONEY Calcium Alginate Dressing.

22 Jun 2010

NCI awards GeneGo Phase II SBIR grant for development of MetaMiner(Oncology) platform

GeneGo, Inc., a leading provider of databases, software and services in systems biology and chemistry, announced today that they were awarded with a Phase II SBIR grant from the National Cancer Institute (NCI) for further development of an analytical platform for translational research and data analysis in oncology.

22 Jun 2010

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced it has received its first purchase order for DAVANAT from PROCAPS S.A., a large, international pharmaceutical company based in Barranquilla, Colombia. Pro-Pharmaceuticals has received a purchase order for $200,000 which will be the upfront payment for this first shipment of DAVANAT.

22 Jun 2010

Pharmaceuticals News and Research

Diet with high fructose, trans fats lead to fatty liver disease with scar tissue

A*STAR physicist receives prestigious 2010 IEEE Medal for Innovations in Healthcare Technology

Prosensa, GSK initiate additional programs for DMD

Regular and long enough intake of EGb 761 protects against Alzheimer's disease: GuidAge study

Nymox reports positive new results from NX02-0014 follow-up study of NX-1207 for BPH

European drugmakers lead in making medicines available to developing world, Index says

OvaGene Oncology opens new advanced molecular research and clinical laboratory facility

Weikang Bio-Technology files for listing on NASDAQ

FDA approves Hospira's meropenem for injection, USP (I.V.)

iCAD image analysis software program used in DCE-MRI studies demonstrated at ASCO 2010

Nuon study confirms potential utility of tranilast as uricosuric agent

Ricerca's Lyon facility obtains ISO 9001:2008 certification

Probactive Biotech, Dalat Nuclear Research Institute enter agreement to co-develop cancer drugs

Ensemble Discovery announces name change to Ensemble Therapeutics Corporation

Affymax's database lock achievement in Phase 3 Hematide trial triggers $30M milestone payment from Takeda

Metabolex signs global development and license agreement with OMJPI

Three leading scientists gather to discuss Improved Strategies for Pre-clinical Cardiac Testing

USPTO issues patent related to Derma Sciences' MEDIHONEY Calcium Alginate Dressing

NCI awards GeneGo Phase II SBIR grant for development of MetaMiner(Oncology) platform

Pro-Pharmaceuticals receives first purchase order for DAVANAT from PROCAPS

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence